Search results
Results from the WOW.Com Content Network
From 1 April 2017 e-visas are granted under three categories of tourist, business and medical. The window for application under e-visa scheme was increased from 30 days to 120 days, and duration of stay on e-visa was increased from 30 days to 60 days, with double entry on e-tourist and e-business visa, and triple entry on e-medical visa. [83]
In most countries, a marketing authorisation is valid for a period of 5 years. After this period, one should apply for renewal of the marketing authorisation, usually by providing minimal data proving that quality, efficacy and safety characteristics are maintained and the risk-benefit ratio of the medicinal product is still favourable.
Marketing Authorisation Application (MAA) is an application submitted by a drug manufacturer seeking marketing authorisation, that is permission to bring a medicinal product (for example, a new medicine or generic medicine) to the market.
Scope of FDA was increased to cover adulterated food as well as tobacco products. Various circle offices were opened in 1971 at city levels. Expansion took place in 1975 and posts of commissioners as well as joint commissioners were created to grant licenses at divisional levels.
It is a law enforcement agency. In 1970, the Government of Maharashtra entrusted the responsibility of enforcement of the Prevention of Food Adulteration Act, 1954 to FDA which is when it got its present name.
Thus Indian passport holders who apply for a Bangladeshi visa in India do not have to pay the visa application fee. [ 38 ] [ 39 ] Russia announced an e-Visa status for parts of the Russian Far East : Primorye and the rest of Khabarovsk , Sakhalin , Chukotka , and Kamchatka regions in 2018, this was later expanded to include Saint Petersburg in ...
It serves a similar function to the Food and Drug Administration (FDA) of the United States or the European Medicines Agency of the European Union. The Indian government has announced its plan to bring all medical devices, including implants and contraceptives under a review of the Central Drugs and Standard Control Organisation (CDSCO).
FDA spends fee revenues to hire, support, and maintain personnel for the oversight of these outsourcing facilities. Outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements under section 501(a)(2)(B) of the FD&C Act and will be inspected by FDA on a risk-based schedule (see sections 503B(a) and 503B(b)(4)).